Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Broncus Holding Corporation
堃博医疗控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2216)

GRANT OF AWARDS PURSUANT TO THE RSU SCHEME

This announcement is made by the Company pursuant to Rules 17.06A, 17.06B and 17.06C of the Listing Rules. The Company announces that on July 28, 2025, the Company granted 352,683 Awards, representing the same number of underlying Shares and approximately 0.07% of the total number of Shares in issue as at the date of this announcement, to 7 Grantees in accordance with the terms of the RSU Scheme, subject to acceptance.

DETAILS OF GRANT OF AWARDS

Grant Date	:	July 28, 2025
Number of Awards granted	:	A total of 352,683 Awards were granted, representing the same number of underlying Shares, to 7 Grantees. All Grantees are employees of the Group and Independent Third Parties.
Purchase Price of the Awards Granted	:	Nil
Closing price of the Shares on the Grant Date	:	HK$2.68 per Share
Vesting Period of the Awards	:	As permitted under the RSU Scheme, a performance-based vesting schedule (in lieu of time-based vesting criteria) is applicable to the Grantees whereby the vesting of the Awards shall be conditional upon the achievement of certain performance indicators. The Awards have a mixed vesting schedule and shall be vested within 3 months from the date of Grant, subject to satisfaction (or waiver, as applicable) of the vesting conditions stipulated in the respective grant letters.

Performance Targets	:	The vesting of the Awards granted to the Grantees will be subject to the individual performance targets as stipulated in the respective grant letters entered into by the Company and each of the Grantees. These performance targets are set against certain benchmark of the functions in which the individual Grantee serves, and are assessed by the Board (or its delegate(s)) from time to time in their sole discretion.
Clawback Mechanisms	:	In the event that a Grantee is found to be negligent in his/her performance of obligations to the Group, acted dishonestly and in violation of his/her fiduciary duties, or otherwise ceases to be an Eligible Participant on the occurrence of any other prescribed events set out in the relevant rules of the RSU Scheme, any unvested Award held by such Grantee on such date shall automatically lapse, unless the Board (or its delegate(s)) determines otherwise at their absolute discretion.
No financial assistance	:	The Group has not provided any financial assistance to the Grantees to facilitate the purchase of Shares under the RSU Scheme.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, none of the Grantees is (i) a Director, a chief executive, a substantial Shareholder, or an associate of any of them; (ii) a participant with options and awards granted and to be granted exceeding the 1% individual limit under Rule 17.03D of the Listing Rules; or (iii) a related entity participant or service provider with options and awards granted and to be granted exceeding 0.1% of the total issued Shares in any 12-month period up to and including the Grant Date (excluding treasury shares). The grant of Awards to the Grantees is not subject to approval by the Shareholders.

REASONS FOR THE GRANT OF AWARDS

The grant of Awards is to reward the Grantees' performance and contributions to the Group, align the interests of the Grantees with those of the Group through ownership of Shares, dividends and other distributions paid on Shares and/or increase in value of Shares, and to encourage and retain the Grantees to make contributions to the long-term growth and profits of the Group.

NUMBER OF SHARES AVAILABLE FOR FUTURE GRANTS

The vesting of all Awards will be funded by Shares held by the Trustee as at the date of this announcement. As at the date of this announcement, after the grant of such Awards, 51,569,883 and 5,271,980 underlying Shares are available for future grant under the Scheme Limit and the Service Provider Sublimit, respectively, of the RSU Scheme as approved at the extraordinary general meeting of the Company held on October 25, 2023.

DEFINITION

In this announcement, the following expressions have the meanings set out below unless the context otherwise requires:

"associate(s)"	shall have the meaning ascribed to it under the Listing Rules;
"Awards"	An award granted by the Board to a selected participant pursuant to the RSU Scheme;
"Board"	the board of Directors;
"Company"	Broncus Holding Corporation (堃博医疗控股有限公司), an exempted company incorporated in the Cayman Islands with limited liability on April 30, 2012, whose Shares were listed and traded on the Stock Exchange;
"Director(s)"	the director(s) of the Company;
"Eligible Participant(s)"	any director and employee (whether full-time or part-time) of the Group, and including persons who are granted Awards as an inducement to enter into employment contracts with these companies;
"Grant Date"	July 28, 2025;
"Grantee(s)"	each or all of seven employees of the Group, who were granted Awards in accordance with the RSU Scheme on the Grant Date;
"Group"	the Company and its subsidiaries;
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong;
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China;
"Independent Third Parties"	third parties independent of the Company and the connected person (as defined in the Listing Rules) of the Company;
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange;
"RSU Scheme"	the restricted share unit scheme of the Company as adopted on May 6, 2021, and amended and restated on July 5, 2021 and October 25, 2023;

"Scheme Limit"	the limit on grant(s) of option(s) and/or award(s) over new Shares under all share schemes of the Company approved by the Shareholders, which must not exceed 52,719,807 (being 10% of the total number of issued Shares as at the date of the Shareholder's approval of the Scheme Limit);
"Service Provider Sublimit"	a sublimit under the Scheme Limit for options and/or awards new Shares of the Company under all share schemes adopted by the Company granted to the service providers, which must not exceed 5,271,980 (being 1% of the total number of issued Shares as at the date of the Shareholder's approval of the Service Provider Sublimit);
"Share(s)"	ordinary share(s) in the share capital of the Company;
"Shareholder(s)"	holder(s) of Shares;
"Stock Exchange"	The Stock Exchange of Hong Kong Limited;
"substantial shareholder"	has the meaning ascribed to it by the Listing Rules; and
"Trustee"	Computershare Hong Kong Trustees Limited, the trustee appointed by the Company to hold Shares on trust for grantees under the RSU Scheme.

By order of the Board
Broncus Holding Corporation
XU Hong
Chairman

Hong Kong, July 28, 2025

As at the date of this announcement, the Board comprises Mr. Hong Xu as executive Director, Mr. Ao Zhang and Ms. Yanhong Kuang as non-executive Directors, and Dr. Pok Man Kam, Ms. Yee Sin Wong and Dr. David Scott Lim as independent non-executive Directors.